ImmuneSense Study- Safety and Efficacy of IGV-001 an Autologus Cell Immunotherapy With Antisense Oligonucleotide (IMV-001) Targeting IGF-1R in Newly Diagnosed Patients With Glioblastoma Multiforme
Enrolling By Invitation
18 years - 99 years
All
Phase
2
6 participants needed
1 Location
Brief description of study
The purpose of this study is to see how safe the study medicine, IGV-001 plus standard of care (SOC), is and to compare IGV-001 with placebo (only standard of care) to see if it works in slowing GBM tumor regrowth.
Participants for this study will be recruited from the patient population that present to the Department of Neurosurgery at the Hospital of the University of Pennsylvania for evaluation and treatment of their brain tumors.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Glioblastoma
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 844939
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
